• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
One-year cardiovascular outcomes after GLP-1 discontinuation

One-year cardiovascular outcomes after GLP-1 discontinuation

by Truveta staff | Sep 3, 2025 | Research

What happens to cardiovascular health when patients stop taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications? That’s the focus of new research from investigators at Baylor Scott & White Research Institute and Stony Brook University Hospital,...
Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)

Truveta experts: Biomarker testing trends in metastatic non-small cell lung cancer (NSCLC)

by Truveta staff | Aug 28, 2025 | Research

Biomarker testing has transformed cancer care over the past decade, opening the door to targeted therapies that can improve outcomes for patients with advanced disease. Yet despite strong guideline recommendations, many patients with metastatic non-small cell lung...
Multiple sclerosis: Real-world treatment patterns and outcomes

Multiple sclerosis: Real-world treatment patterns and outcomes

by Truveta staff | Aug 25, 2025 | Research

Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines from leading MS experts have increasingly emphasized the importance of early intervention...
ISPE 2025: Real-world data survival patterns in glioblastoma patients

ISPE 2025: Real-world data survival patterns in glioblastoma patients

by Truveta Research | Aug 22, 2025 | Research, Research Insights

Authors: Mantas Dmukauskas, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Amy Wu ⊕Truveta, Inc, Bellevue, WA The survival rate for patients with glioblastoma (GBM) differs significantly by...
ISPE 2025: Active surveillance of mosquito-borne diseases in the United States

ISPE 2025: Active surveillance of mosquito-borne diseases in the United States

by Truveta Research | Aug 22, 2025 | Research, Research Insights

Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
ISPE 2025: Active surveillance of foodborne diseases in the United States

ISPE 2025: Active surveillance of foodborne diseases in the United States

by Truveta Research | Aug 22, 2025 | Research, Research Insights

Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-time monitoring of respiratory virus-associated hospitalizations: Trends through November 2025 
  • Rising use of GLP-1 medications among women with PCOS
  • Advancing biomedical AI: Enhancing BERT performance with LLM-generated annotations

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.